摘要
目的观察厄贝沙坦联合曲美他嗪治疗扩张型心肌病心力衰竭的临床效果。方法选取医院收治的扩张型心肌病心力衰竭患者84例为研究对象,随机分为观察组和对照组,每组42例。对照组给予常规措施对症治疗,观察组在对照组治疗基础上给予厄贝沙坦联合曲美他嗪治疗。观察2组患者治疗前后心功能指标、N末端脑钠肽(NT-proBNP)、脑钠肽(BNP)变化情况,比较2组临床疗效。结果治疗前,2组患者心功能指标、NT-proBNP和BNP水平比较差异均无统计学意义(P>0.05);治疗后,2组心功能指标、NT-proBNP和BNP水平均得到不同程度改善,观察组改善更明显,且观察组治疗总有效率为95.24%,高于对照组的73.81%,差异均有统计学意义(P<0.01)。结论厄贝沙坦联合曲美他嗪治疗扩张型心肌病心力衰竭疗效确切,可明显改善患者心功能,降低机体应激反应,提高临床疗效。
Objective To analyze the curative effect of irbesartan combined with Trimetazidine in the treatment of heart failure with dilated heart disease. Methods 84 cases of patients with dilated cardiomyopathy heart failure selected as the object of observation,were randomly divided into observation group and control group with 42 cases in each group. The control group was given routine symptomatic treatment measures and the experimental group,on the basis of control group,was the given Tanzania Trimetazidine treatment combined with irbesartan. The changes of cardiac function,N-terminal brain natriuretic peptide（ BNP） and brain natriuretic peptide（ BNP） were observed before and after treatment. The clinical efficacy of the two groups was compared. Results The cardiac function index,NT-proBNP and BNP in the two groups were no significant difference before treatment（ P〉0. 05）; After treatment,the two groups of cardiac function,NT-proBNP and BNP levels were improved to varying degrees,and the observation group has more obvious improvements,and the total effective rate of observation group was 95. 24%,higher than the control group of 73. 81%. The difference was statistically significant（ P〈0. 01）. Conclusion The curative effect of irbesartan combined with Trimetazidine in the treatment of heart failure with dilated heart disease is productive,which can well improve the cardiac function,reduce the stress reaction and improve the curative effect.
出处
《临床合理用药杂志》
2017年第32期1-3,共3页
Chinese Journal of Clinical Rational Drug Use
